Miklos Peterfy, Ph.D.
Professor of Biochemistry
College of Osteopathic Medicine of the Pacific
Join year: August 2016
Postdoctoral Fellow, National Institutes of Health, Bethesda, MD,1990-1993
PhD, Budapest University of Technology, Hungary, 1990
BS, Budapest University of Technology, Hungary, 1986
Professor, Department of Biomedical Sciences, COMP, Western University of Health Sciences, 2016-pres
Visiting Scientist, Cedars-Sinai Medical Center, 2016-pres
Visiting Professor, Department of Medicine, UCLA School of Medicine, 2016-2020
Adjunct Professor, Department of Medicine, UCLA School of Medicine, 2013-2016
Associate Professor, Director, Laboratory of Murine Models for Metabolic Disease, Obesity and Diabetes Research Institute, Cedars-Sinai Medical Center, 2007-2016
Associate Professor, Department of Medicine, UCLA School of Medicine, 2007-2013
Assistant Professor, Department of Medicine, UCLA School of Medicine, 2001-2007
Assistant Research Biochemist, Department of Medicine, UCLA, 1998-2001
Research Scientist, Amgen Inc., 1993-1998
TEACHING
Western University of Health Sciences:
Endocrine System (FOM7), COMP, WUHS, 2017-pres
Biochemistry/Genetics (ISOM, FOM3-5), COMP, WUHS, 2016-pres
Courses Chaired/co-Chaired:
Mouse Molecular Genetics (C122/C222), UCLA, 2017-2018
Genetics, Cedars-Sinai PhD Program, 2012-2016
Human Genetics & Genomics (CM256), UCLA, 2003-2016
Additional Lecturing:
Problem-Based Learning, UCLA School of Medicine, 2014
Medical Genetics Training Program, UCLA, 2009-2014
Cardiovascular Biology, Cedars-Sinai PhD Program, 2009-2013
Oncology, Cedars-Sinai PhD Program, 2009-2011
Genetics, Cedars-Sinai PhD Program, 2008
Topics in Genomics (HG210), UCLA, 2007
Mouse Molecular Genetics (CM222), UCLA, 2005
Advanced Human Genetics (HG236), UCLA, 2002
Research in the Peterfy Laboratory focuses on the molecular basis of common metabolic diseases including diabetes, dyslipidemia and coronary artery disease. We use genetic approaches to identify novel determinants and mechanisms responsible for metabolic abnormalities with the goal of providing the foundation for novel therapeutic approaches.
NIH/NIDDK (R01-DK129877), PI: Peterfy/Najjar, Project period: 4/1/22-3/31/26, Novel Molecular Determinants of Insulin Clearance.
NIH/NHLBI (R15-HL154071), PI: Peterfy, Project period: 6/14/21-6/13/25, Lipase Maturation Factor 1 in Hypertriglyceridemia
DOD CDMRP (GRANT13363192), PI: Peterfy, Project period: 7/1/22-6/30/25, Hepatic Insulin Clearance: A Novel Therapeutic Target in Type 2 Diabetes
NIH/NHLBI (R01-HL127155), PI Peterfy, Project period: 7/1/15-4/30/20, Molecular Mechanisms of Lipase Maturation and Secretion
NIH/NHLBI (P01-HL28481), PL Peterfy (PD Lusis), Project period: 7/1/10-6/30/15, Lmf1 in Lipase Expression and Lipid Metabolism
NIH/NHLBI (P01-HL28481), PL Peterfy (PD Lusis), Project period: 2/1/05-1/31/10, Lipase Expression and its Role in the Metabolic Syndrome
American Diabetes Association (1-05-RA-96), PI Peterfy,Project period: 1/1/05-12/31/07, Positional Cloning of a Diabetes-Susceptibility Locus in a Mouse Model of Type 2 Diabetes
American Diabetes Association (023018), PI Peterfy, Project period: 1/1/00-12/31/02, Functional Characterization of a Novel Gene Involved in Insulin Signaling
Talari, N. K., Mattam, U., Kamisnka, D., Sotomayor-Rodriguez, I., Rahman, A. P., Peterfy, M.,Pajukanta, P., Pihlajamäki, J., Krishnan, K. C. (2024) Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and de novo lipogenesis. iScience, 27: 109709.
Krishnan, K. C., Vergnes, L., Acin-Perez, R., Stiles, L., Shum, M., Ma, L., Mouisel, E., Pan, C., Moore, T. M.,Peterfy, M., Romanoski, C. E., Reue, K., Bjorkegren, J. L. M., Laakso, M., Liesa, M., Lusis, A. J. (2021) Sex-specific genetic regulation of adipose mitochondria and metabolic syndrome by Ndufv2.Nat. Metab., 13: 1552-1568.
Guo, F., Seldin, M.,Peterfy, M, Charugundla, S., Zhou, Z., Lee, S. D., Mouton, A., Rajbhandari, P., Zhang, W., Pellegrini, M., Tontonoz, P., Lusis, A. J., Shih, D. M. (2021) Notum promotes thermogenesis and protects against diet-induced obesity and insulin resistance in mice.Sci. Rep., 11: 16409.
Norheim, F., Krishnan, K. C., Bjellaas, T., Vergnes, L., Pan, C., Parks, B. W., Meng, Y., Lang, J., Ward, J. A., Reue, K., Mehrabian, M., Gundersen, T. E.,Peterfy, M., Dalen, K. T., Drevon, C. A., Hui, S. T., Lusis, A. J., Seldin, M. M. (2020) Genetic regulation of liver lipids in a mouse model of insulin resistance and hepatic steatosis.Mol. Systems Biol., 17: e9684.
Krishnan, K. C., Floyd, R. R., Sabir, S., Jayasekera, D. W., Leon-Mimila, P. V., Jones, A. E., Cortez, A. A., Shravah, V.,Peterfy, M., Stiles, L., Canizales-Quinteros, S., Huertas-Vazquez, A., Lusis, A. J. (2020): Liver pyruvate kinase promotes NAFLD/NASH in both mice and humans in a sex-specific manner.Cell. Mol. Gastroenterol. Hepat., 14: S2352.
Krishnan, K. C., Sabir, S., Shum, M., Lang, J. M., Floyd, R. R., Acin-Perez, R., Vergnes, L., Seldin, M. M., Fuqua, B. K., Jayasekera, D. W., Nand, S. K., Anum, D. C., Pan, C., Stiles, L.,Peterfy, M., Reue, K., Liesa, M., Lusis, A. J. (2019): Sex-specific metabolic functions of adipose Lipocalin-2.Mol. Metab., 30: 30-47.
Ehrhardt, N., Cui, J., Dagdeviren, S., Saengnipanthkul, S., Goodridge, H. S., Kim, J. K., Lantier, L., Guo, X., Chen, Y. I., Raffel, L. J., Buchanan, T. A., Hsueh, W. A., Rotter, J. I., Goodarzi, M. O., Peterfy, M. (2019) Adiposity-Independent Effects of Aging on Insulin Sensitivity and Clearance in Mice and Humans.Obesity27: 434-443.
Peterfy, M., Bedoya, C., Giacobbe, C., Pagano, C., Gentile, M., Rubba, P., Fortunato, G., Di Taranto, M. D. (2018) Characterization of two novel pathogenic variants at compound heterozygous status in Lipase Maturation Factor 1 (LMF1) gene causing severe hypertriglyceridemia.J. Clin. Lipidol. 12: 1253-1259.
Ehrhardt, N., Doche, M. E., Chen, S., Mao, H. Z., Walsh, M. T., Bedoya, C., Guindi, M., Xiong, W., Irudayam, J. I., Iqbal, J., Fuchs, S., French, S. W., Hussain, M. M., Arditi, M., Arumugaswami, V.,Peterfy, M. (2017) Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.Hum. Mol. Gen. 26: 2719-2731.
Labadzhyan, A., Cui, J.,Peterfy, M., Guo, X., Chen, Y.I., Hsueh, W.A., Rotter, J.I., Goodarzi, M.O. (2016) Insulin clearance is associated with hepatic lipase activity and lipid and adiposity traits in Mexican Americans.PLOS One11: e0166263.
Sha, H., Francisco, A., Ehrhardt, N., Sun, S., Xue, Z., Liu, L., Guber, R., Panhwar, M. S., Hang, S., Xue, B., Brenna, J. T., Kersten, S., Bensadoun, A.,Peterfy, M.*, Long, Q.*, Qi, L.* (2014) The ER-Associated degradation adapter protein Sel1L regulates triglyceride metabolism via lipoprotein lipase.Cell Metab., 20: 458-470. *co-senior authors
Ehrhardt, N., Bedoya, C.,Peterfy, M.(2014) Embryonic viability, lipase deficiency, hypertriglyceridemia and neonatal lethality in a novel LMF1-deficient mouse model.Nutr. Metab. 11: 37-45.
Mao, H. Z., Ehrhardt, N., Bedoya, C., Gomez, J. A., DeZwaan-McCabe, D., Mungrue, I. N., Kaufman, R. J., Rutkowski, D. T.,Peterfy, M.(2014) Lipase Maturation Factor 1 is Induced by Endoplasmic Reticulum Stress Through Atf6α Signaling.J. Biol. Chem. 289: 24417-24427.
Hosseini, M., Ehrhardt, N., Weissglas-Volkov, D., Lai, C-M., Mao, H. Z.., Liao, J., Nikkola, Bensadoun, A., E., Taskinen, M-R., Doolittle, M. H., Pajukanta, P.,Peterfy, M. (2012) Transgenic expression and variation of LMF1 affect LPL activity in mice and humans.Arterioscler. Thromb. Vasc. Biol., 32: 1204-1210.